$KTTA

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 10, 2025 in NYC.

Original reporting
GlobeNewswire · Pasithea
Published Aug 28, 2025, 11:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2025, 12:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference — source image
Decision brief

The 30-second read

$KTTABullishMed
01

Why it matters

Positive clinical trial updates often lead to increased investor confidence and stock appreciation, especially when presented at prominent conferences.

02

Market read

The event is highly relevant for biotech investors and analysts tracking clinical trial progress and pipeline developments.

03

What to watch

Market-wide volatility, broader biotech sector trends, and potential delays or setbacks in clinical trials could mitigate positive effects.

Timing: High, as the event is scheduled for September 10, 2025.

Background

Pasithea Therapeutics is a biotech company focused on developing novel therapies for neurological and psychiatric disorders. The upcoming presentation at H.C. Wainwright's conference is a key event to showcase progress on PAS-004, a drug candidate in clinical trials.

Company-level read

Ticker impact

$KTTABullishMedium confidence
Context

High relevance due to upcoming presentation at a major investment conference.

Expected impact

Potential short-term increase of 5-10% in stock price following the presentation, contingent on positive reception and clinical data disclosure.

Evidence & confidence

The presentation at a major conference often leads to increased investor interest, especially if new positive data is shared. However, the impact depends on the content of the presentation and market conditions.

Market effects

Potential positive sentiment for biotech sector, especially for companies with ongoing clinical trials.

Limited regional impact, primarily affecting US biotech stocks.

Moderate, as biotech conferences attract international investors and analysts.

Counterpoint

The presentation may not lead to a significant stock movement if the clinical progress is in line with existing expectations or if market conditions are unfavorable.

Key entities

  • Pasithea Therapeutics

    Biotech firm developing therapies for neurological and psychiatric conditions.

  • PAS-004

    Clinical-stage therapeutic under development for neurological disorders.

Related articles

$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.